Answers are grounded in this paper and cite their sources.
Although tourniquets and tranexamic acid (TXA) are commonly used in total knee arthroplasty (TKA), evidence regarding their combined effects remains limited. This study investigated the effects of tourniquet use and TXA administration on intraoperative blood loss, surgical field visualization, and postoperative knee function following primary TKA. This partially blinded randomized clinical trial with a 2 × 2 factorial design was conducted at a tertiary academic center between December 2023 and December 2024. A total of 136 patients undergoing primary unilateral TKA were randomly assigned to four groups ( n = 34 each): Group A (no tourniquet, no TXA), Group B (tourniquet + TXA), Group C (tourniquet only), and Group D (TXA only). In groups B and D, 1000 mg of TXA was administered intravenously approximately 30 min before incision, followed by1000 mg administered intra-articularly at the end of surgery. The primary outcome was intraoperative blood loss. Secondary outcomes included pain Visual Analogue Scale (VAS), the Western Ontario and McMaster Universities Arthritis Index (WOMAC), and the Oxford Knee Score (OKS). Factorial analyses, evaluated the main effects of tourniquet use and TXA administration, and their interaction. Baseline characteristics were comparable across groups. Mean intraoperative blood loss was substantially lower in Groups B and C (122.1 ± 70.9 mL and 113.2 ± 66.9 mL, respectively) than in Groups A and D (325.8 ± 78.2 mL and 279.4 ± 102.1 mL, respectively). Factorial analysis demonstrated a significant main effect of tourniquet use on intraoperative blood loss, whereas TXA had no significant independent main effect. A significant TXA × tourniquet interaction was also observed. Tourniquet use also significantly improved surgeon-rated surgical field visualization. Although postoperative hemoglobin (Hgb) and hematocrit (Hct) levels decreased significantly, these changes were not significantly influenced by TXA, tourniquet use, or their interaction. Pain VAS, WOMAC, and OKS improved significantly over time. TXA had a modest significant main effect on VAS score, with lower estimated marginal mean pain scores in the no-TXA group; however, no significant TXA × time interaction was observed. WOMAC and OKS were not significantly affected by TXA or tourniquet use, and no significant treatment × time interactions were detected. Tourniquet use significantly reduced visible intraoperative blood loss and improved surgical visualization in primary TKA. However, these benefits did not translate into a significant reduction in estimated total blood loss. TXA had no significant independent effect on intraoperative blood loss. Neither intervention significantly influenced postoperative hematologic changes or short-term functional recovery. These findings suggest that the main benefit of tourniquet use may lie in improving intraoperative surgical conditions rather than postoperative recovery. Randomized Clinical Trial, Level I. Iranian Registry of Clinical Trials (IRCT), Clinical trial number: IRCT20221228056952N1, Trial ID: 67663, Registration date: 2023/12/30, Available at: http://www.irct.ir/ .
No takes yet. Share an insight, caveat, or question.
Ganji et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: